The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Intravitreal triamcinolone acetonide for exudative age related macular degeneration
Open accessAbstract
AIM: To evaluate the effect of intravitreal triamcinolone acetonide on the visual acuity of patients with exudative age related macular degeneration, to assess the duration of a possible effect, and to evaluate clinical side effects of the treatment. METHODS: The study included 67 patients (71 eyes) who presented with exudative age related macular degeneration of predominantly or total occult type (n = 68) or classic type (n = 3), and who received once, or repeatedly, an intravitreal injection of 25 mg of crystalline triamcinolone acetonide. Mean follow up time was 7.46 (SD 3.54) months (range 3.1-19.57 months). RESULTS: Visual acuity increased significantly (p <0.001) from 0.16 (0.11) to a mean maximum of 0.23 (0.17). Postoperative visual acuity was highest 1-3 months after the injection. 47 (66.2%) eyes gained in maximal visual acuity and 11 (15.5%) eyes lost in visual acuity. Intraocular pressure increased significantly (p <0.001) from 15.1 (3.1) mm Hg at baseline to a maximal value of 23.0 (8.25) mm Hg. At the end of follow up, intraocular pressure again decreased significantly (p<0.001) to 16.8 (4.9) mm Hg. No cases of postoperative infectious endophthalmitis, rhegmatogenous retinal detachment, or proliferative vitreoretinopathy occurred. Owing to a decrease in visual acuity after an initial increase, six patients received a second intravitreal triamcinolone acetonide injection after which visual acuity increased again in three eyes. CONCLUSIONS: Intravitreal injection of 25 mg of crystalline triamcinolone acetonide merits further study for the treatment of exudative age related macular degeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Prevalence of age-related maculopathy in Australia
Mitchell, P., Smith, W., Attebo, K., & Wang, J. J. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)30846-9 · Cited by 1,062
Intravitreal triamcinolone for refractory diabetic macular edema
Martidis, A., Duker, J. S., Greenberg, P. B., Rogers, A. H., Puliafito, C. A., Reichel, E., & Baumal, C. (2002) · Ophthalmology · doi:10.1016/s0161-6420(02)00975-2 · Cited by 1,032
The Prevalence of Age-related Maculopathy in the Rotterdam Study
Vingerling, J. R., Dielemans, I., Hofman, A., Grobbee, D. E., Hijmering, M., Kramer, C. F. L., & de Jong, P. T. V. M. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)31034-2 · Cited by 815
Age-related macular degeneration
Bressler, N. M., Bressler, S. B., & Fine, S. L. (1988) · Survey of Ophthalmology · doi:10.1016/0039-6257(88)90052-5 · Cited by 681
Ophthalmoscopic Evaluation of the Optic Nerve Head
Jonas, J. B., Budde, W. M., & Panda-Jonas, S. (1999) · Survey of Ophthalmology · doi:10.1016/s0039-6257(98)00049-6 · Cited by 607
Self-citationBressler, N. M. (2001) · Cited by 599
Intravitreal Injection of Triamcinolone for Diffuse Diabetic Macular Edema
Jonas, J. B. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.1.57 · Cited by 563
Self-citationIntravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study
Antcliff, R. J., Spalton, D. J., Stanford, M. R., Graham, E. M., ffytche, T. J., & Marshall, J. (2001) · Ophthalmology · doi:10.1016/s0161-6420(00)00658-8 · Cited by 487
Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema
Jonas, J. B., & Söfker, A. (2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)01010-8 · Cited by 481
Self-citationINTRAVITREAL TRIAMCINOLONE ACETONIDE IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION
DANIS, R. P., CIULLA, T. A., & PRATT, W. A. (2000) · Retina · doi:10.1097/00006982-200003000-00004 · Cited by 423
Intraocular pressure after intravitreal injection of triamcinolone acetonide
Jonas, J. B. (2003) · British Journal of Ophthalmology · doi:10.1136/bjo.87.1.24 · Cited by 422
Self-citationIntravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion
Greenberg, P. B. (2002) · British Journal of Ophthalmology · doi:10.1136/bjo.86.2.247 · Cited by 370
Schmidt-Erfurth, U. (1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.9.1177 · Cited by 364
Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis
Young, S., Larkin, G., Branley, M., & Lightman, S. (2001) · Clinical & Experimental Ophthalmology · doi:10.1046/j.1442-9071.2001.00360.x · Cited by 352
Treatment of Intraocular Proliferation with Intravitreal Injection of Triamcinolone Acetonide
Tano, Y., Chandler, D., & Machemer, R. (1980) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)75196-7 · Cited by 338
Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up
Challa, J. K., Gillies, M. C., Penfold, P. L., Gyory, J. F., Hunyor, A. B., & Billson, F. A. (1998) · Australian and New Zealand Journal of Ophthalmology · doi:10.1111/j.1442-9071.1998.tb01330.x · Cited by 324
The Lack of Toxicity of Intravitreally Administered Triamcinolone Acetonide
McCuen, B. W., Bessler, M., Tano, Y., Chandler, D., & Machemer, R. (1981) · American Journal of Ophthalmology · doi:10.1016/0002-9394(81)90013-1 · Cited by 262
Intravitreal triamcinolone and elevated intraocular pressure
Fracs, R. J. B. W., & Fracs, P. E. B. (1999) · Australian and New Zealand Journal of Ophthalmology · doi:10.1046/j.1440-1606.1999.00238.x · Cited by 245
Jonas, J. B., Hayler, J. K., Söfker, A., & Panda-Jonas, S. (2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00882-5 · Cited by 241
Self-citationFluocinolone acetonide sustained drug delivery device to treat severe uveitis
Jaffe, G. J., Ben-nun, J., Guo, H., Dunn, J. P., & Ashton, P. (2000) · Ophthalmology · doi:10.1016/s0161-6420(00)00466-8 · Cited by 234
Kwak, H. W. (1992) · Archives of Ophthalmology · doi:10.1001/archopht.1992.01080140115038 · Cited by 228
Exudative macular degeneration and intravitreal triamcinolone A pilot study
Penfold, P. L., Gyory, J. F., Hunyor, A. B., & Billson, F. A. (1995) · Australian and New Zealand Journal of Ophthalmology · doi:10.1111/j.1442-9071.1995.tb00179.x · Cited by 221
Hida, T., Chandler, D., Arena, J. E., & Machemer, R. (1986) · American Journal of Ophthalmology · doi:10.1016/0002-9394(86)90593-3 · Cited by 217
Inhibition of Intraocular Proliferations with Intravitreal Corticosteriods
Tano, Y., Sugita, G., Abrams, G., & Machemer, R. (1980) · American Journal of Ophthalmology · doi:10.1016/0002-9394(80)90239-1 · Cited by 213
Jonas, J. B. (2000) · British Journal of Ophthalmology · doi:10.1136/bjo.84.9.1064 · Cited by 193
Self-citationIshibashi, T., Miki, K., Sorgente, N., Patterson, R., & Ryan, S. J. (1985) · Archives of Ophthalmology · doi:10.1001/archopht.1985.01050050100026 · Cited by 190
Ciulla, T. A. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.3.399 · Cited by 182
Penfold, P. L., Wen, L., Madigan, M. C., Gillies, M. C., King, N. J. C., & Provis, J. M. (2001) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.2000.01316.x · Cited by 167
Martidis, A., Duker, J. S., & Puliafito, C. A. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.9.1380 · Cited by 160
Penn, J. S., Rajaratnam, V. S., Collier, R. J., & Clark, A. F. (2001) · PubMed · Cited by 159
Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device.
Jaffe, G. J., Yang, C., Guo, H., et al. (2000) · PubMed · Cited by 149
Danis, R. P., Bingaman, D. P., Yang, Y., & Ladd, B. S. (1996) · Ophthalmology · doi:10.1016/s0161-6420(96)30383-7 · Cited by 146
Age-related macular degeneration
Boldt, H. C., Bressler, S. B., Fine, S. L., & Bressler, N. M. (1990) · Current Opinion in Ophthalmology · doi:10.1097/00055735-199006000-00008 · Cited by 126
Ranson, N. (2002) · British Journal of Ophthalmology · doi:10.1136/bjo.86.5.527 · Cited by 111
The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization
Antoszyk, A. N., Gottlieb, J. L., Machemer, R., & Hatchell, D. L. (1993) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/bf01681698 · Cited by 103
Intravitreal injection of triamcinolone acetonide as treatment for chronic uveitis
Degenring, R. F. (2003) · British Journal of Ophthalmology · doi:10.1136/bjo.87.3.361 · Cited by 103
Penfold, P. L., Wong, J. G., Gyory, J., & Billson, F. A. (2001) · Clinical & Experimental Ophthalmology · doi:10.1046/j.1442-9071.2001.00407.x · Cited by 97
Retinal Toxicity of Triamcinolone Acetonide in Silicone-Filled Eyes
Kivilcim, M., Peyman, G. A., El-Dessouky, E. S., Kazi, A. A., Cheema, R., & Hegazy, H. M. (2000) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/1542-8877-20001101-07 · Cited by 78
Jonas, J. B., Kreissig, I., & Degenring, R. F. (2002) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-002-0547-y · Cited by 74
Self-citationBerger, A., Cheng, C.-K., Pearson, P. A., Ashton, P., Crooks, P. A., Cynkowski, T., Cynkowska, G., & Jaffe, G. J. (1996) · PubMed · Cited by 67
Concentration of intravitreally injected triamcinolone acetonide in intraocular silicone oil
Jonas, J. B. (2002) · British Journal of Ophthalmology · doi:10.1136/bjo.86.12.1450-a · Cited by 45
Self-citationIntravitreal triamcinolone in recurrence of choroidal neovascularisation
Penfold, P. L. (2002) · British Journal of Ophthalmology · doi:10.1136/bjo.86.6.600 · Cited by 36
Cited by
Intravitreal triamcinolone for refractory diabetic macular edema
Martidis, A., Duker, J. S., Greenberg, P. B., Rogers, A. H., Puliafito, C. A., Reichel, E., & Baumal, C. (2002) · Ophthalmology · doi:10.1016/s0161-6420(02)00975-2 · Cited by 1,032
The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration
Wong, T., Chakravarthy, U., Klein, R., Mitchell, P., Zlateva, G., Buggage, R., Fahrbach, K., Probst, C., & Sledge, I. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.008 · Cited by 601
RISKS OF INTRAVITREOUS INJECTION: A COMPREHENSIVE REVIEW
JAGER, R. D., AIELLO, L. P., PATEL, S. C., & CUNNINGHAM, E. T. (2004) · Retina · doi:10.1097/00006982-200410000-00002 · Cited by 572
Beer, P. M., Bakri, S. J., Singh, R. J., Liu, W., Peters, G. B., & Miller, M. (2003) · Ophthalmology · doi:10.1016/s0161-6420(02)01969-3 · Cited by 570
Intravitreal Injection of Triamcinolone for Diffuse Diabetic Macular Edema
Jonas, J. B. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.1.57 · Cited by 563
Self-citation
Metadata
- Authors
- Jonas, J. B.
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2003-04-01
- Volume
- 87
- Issue
- 4
- Pages
- 462-468
- ISSN
- 0007-1161 (ISSN-L)
- OpenAlex
- W2170353976
- Cited by
- 492
- References
- 44
- FWCI
- 83.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.